2017_SBRT_Course Book
Trials on targeted therapies for patients with BM
Entity
n Targeted Therapies Intracranial response rate
OS (months)
NSCLC BM; EGFR status unknown 23 Gefitinib or erlotinib
73,9%
18,8
1-3 BSCLC BM; EGFR status unknown
41 Erlotinib plus WBRT and SRS
NA
6.1
NSCLC BM Alk rearrangement
27 5
Crizotinib Crizotinib plus SRT
56,0% 65,0%
13,2 intra- cranial TTP
HER2-positive breast cancer BM 45 Trastuzumab (T-DM1 ) +chemo plus local therapy Oligosymp. Her2-positiv breast BM 45 Laptinib plus capecitabine
NA
26.8
66,0%
17
BRAF mutated melanoma BM 74 Dabrafenib
39.2%
8,3
BRAF mutated melanoma BM 24 Vemurafenib
42,0%
5,3
Combined strategies may improve antitumor activity
Future of targeted therapy for BM
Made with FlippingBook Annual report